Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Intrinsic Value
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. [ Read More ]
The intrinsic value of one PHAT stock under the Base Case scenario is 12.05 USD. Compared to the current market price of 11.05 USD, Phathom Pharmaceuticals Inc is Undervalued by 8%.
Valuation Backtest
Phathom Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling PHAT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Phathom Pharmaceuticals Inc's business.
What risks and challenges
does Phathom Pharmaceuticals Inc face in the near future?
Summarize the latest earnings report
of Phathom Pharmaceuticals Inc.
Provide P/E
for Phathom Pharmaceuticals Inc and its competitors.
Balance Sheet Decomposition
Phathom Pharmaceuticals Inc
Current Assets | 397.4m |
Cash & Short-Term Investments | 381.4m |
Receivables | 1.6m |
Other Current Assets | 14.4m |
Non-Current Assets | 16.4m |
PP&E | 3.6m |
Other Non-Current Assets | 12.8m |
Current Liabilities | 38.8m |
Accounts Payable | 12.6m |
Accrued Liabilities | 19.1m |
Other Current Liabilities | 7.1m |
Non-Current Liabilities | 447.8m |
Long-Term Debt | 437.7m |
Other Non-Current Liabilities | 10.2m |
Earnings Waterfall
Phathom Pharmaceuticals Inc
Revenue
|
682k
USD
|
Cost of Revenue
|
-167k
USD
|
Gross Profit
|
515k
USD
|
Operating Expenses
|
-167.8m
USD
|
Operating Income
|
-167.3m
USD
|
Other Expenses
|
-34.3m
USD
|
Net Income
|
-201.6m
USD
|
Free Cash Flow Analysis
Phathom Pharmaceuticals Inc
What is Free Cash Flow?
PHAT Profitability Score
Profitability Due Diligence
Phathom Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Phathom Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
PHAT Solvency Score
Solvency Due Diligence
Phathom Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Phathom Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHAT Price Targets Summary
Phathom Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for PHAT is 23.17 USD with a low forecast of 10.1 USD and a high forecast of 29.4 USD.
Ownership
PHAT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PHAT Price
Phathom Pharmaceuticals Inc
Average Annual Return | -11.55% |
Standard Deviation of Annual Returns | 33.59% |
Max Drawdown | -89% |
Market Capitalization | 566.7m USD |
Shares Outstanding | 51 289 100 |
Percentage of Shares Shorted | 21.55% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Contact
IPO
Employees
Officers
The intrinsic value of one PHAT stock under the Base Case scenario is 12.05 USD.
Compared to the current market price of 11.05 USD, Phathom Pharmaceuticals Inc is Undervalued by 8%.